Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2)
Goel, Shom, O'Shaughnessy, Joyce, Tan, Antoinette R., Krastev, Boris Milev, Rugo, Hope S., Aftimos, Philippe Georges, Yardley, Denise A., Zoran, Andric, Wolfgang, Curt Douglas, Sorrentino, Jessica, Tao, Wenli, Beelen, Andrew Paul, Malik, Rajesh K., Jain, Sarika
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results
Maglakelidze, Marina, Bulat, Iurie, Ryspayeva, Dinara, Krastev, Boris Milev, Gogiladze, Maia, Crijanovschi, Adrian, Aftimos, Philippe Georges, Neven, Patrick, Pegram, Mark D., Menke, Catharina Wilhelmina, Dees, Elizabeth Claire, Schroder, Carolien P., Jager, A., Chap, Linnea I., Hamilton, Erika P., Cristofanilli, Massimo, Ulahannan, Susanna Varkey, Boers, Jorianne, Iqbal, Ramsha, Jain, Sarika
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article